KR102506968B1 - A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof - Google Patents
A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof Download PDFInfo
- Publication number
- KR102506968B1 KR102506968B1 KR1020220122046A KR20220122046A KR102506968B1 KR 102506968 B1 KR102506968 B1 KR 102506968B1 KR 1020220122046 A KR1020220122046 A KR 1020220122046A KR 20220122046 A KR20220122046 A KR 20220122046A KR 102506968 B1 KR102506968 B1 KR 102506968B1
- Authority
- KR
- South Korea
- Prior art keywords
- suture
- pcl
- pla
- present
- placl
- Prior art date
Links
- 229920002988 biodegradable polymer Polymers 0.000 title claims abstract description 6
- 239000004621 biodegradable polymer Substances 0.000 title claims abstract description 6
- 239000011342 resin composition Substances 0.000 title claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims abstract description 6
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 4
- 230000006835 compression Effects 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 abstract description 16
- 239000007924 injection Substances 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 15
- 238000001746 injection moulding Methods 0.000 abstract description 9
- 238000012545 processing Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 16
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 16
- 239000002994 raw material Substances 0.000 description 15
- 239000008188 pellet Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000001125 extrusion Methods 0.000 description 6
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 description 5
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- -1 aliphatic aldehydes Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012778 molding material Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 101000691618 Homo sapiens Inactive phospholipase C-like protein 1 Proteins 0.000 description 1
- 102100026207 Inactive phospholipase C-like protein 1 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 235000012438 extruded product Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Chemical group CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920000848 poly(L-lactide-ε-caprolactone) Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000209 wet digestion Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
- C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
본 발명은 고기능 봉합사 제조용 생분해성 고분자 수지 조성물 및 이로부터 제조된 고기능 봉합사에 관한 것으로, 인체에 무해하고 안전하며 사용 후 생분해되어 친환경적이고, 사출성형시 가공물성이 우수하며, 연신율이 높아 사출 후 봉합사로의 연성(늘림성과 늘림 안정성)이 크게 향상되는 것에 관한 것이다.The present invention relates to a biodegradable polymer resin composition for manufacturing a high-function suture and a high-function suture prepared therefrom, which is harmless to the human body, safe, biodegradable after use, environmentally friendly, excellent in processing properties during injection molding, and high in elongation, so that the suture after injection It is about greatly improving furnace ductility (stretchability and stretchability stability).
피부 노화를 방지하기 위해, 화장품, 마사지 등의 이용이 꾸준히 증가하고 있고, 최근에는 피부주름 개선 시술이 널리 행해지고 있다. In order to prevent skin aging, the use of cosmetics, massage, etc. is steadily increasing, and recently, skin wrinkle improvement procedures have been widely performed.
피부주름 개선 시술에는 안면 리프트(Face lift)와 같은 직접적 방법과 리프팅 시술과 같은 간접적 방법이 있다.Skin wrinkle improvement procedures include a direct method such as a face lift and an indirect method such as a lifting procedure.
안면 리프트는 피부를 위로 끌어당겨 여분의 피부를 절제한 후 꿰매 피부를 탱탱하게 하는 시술을 말한다. A face lift refers to a procedure in which the skin is pulled upward to remove excess skin and then stitched to tighten the skin.
이 시술은 효과가 빠르기는 하지만, 수술 위험도가 높고, 귀 앞과 이마 라인에 흉터가 남을 수 있으며, 회복 기간도 1개월 넘게 걸려 선뜻 선택하기가 쉽지 않다. Although this procedure is effective, the risk of surgery is high, scars may remain in front of the ears and the forehead line, and the recovery period is over a month, so it is not easy to choose.
게다가, 노화된 피부는 주름이 계속 진행될 뿐 아니라 피부가 얇아져 오히려 노화가 빨라지는 문제도 있다.In addition, aging skin not only continues to develop wrinkles, but also has a problem of accelerated aging due to thin skin.
리프팅 시술은 인체에 무해한 봉합사를 피부 내에 삽입하여 피부 조직에 자극을 줌으로써, 피부 수축 및 재생을 촉진하고, 나아가 봉합사의 장력을 이용하여 피부 조직과 유착된 부분을 위쪽으로 당겨 고정함으로써 늘어진 피부 조직을 리프팅한다. The lifting procedure stimulates the skin tissue by inserting a suture harmless to the human body into the skin, thereby promoting skin contraction and regeneration, and furthermore, by using the tension of the suture to pull the part adhered to the skin tissue upward to fix it, the sagging skin tissue is lifted. Lift up.
이 시술은 기존의 수술적 시술에 비해 시술이 간단하고 일상 생활에 지장을 거의 주지 않아, 최근 많이 이용되고 있다.Compared to conventional surgical procedures, this procedure is simple and rarely interferes with daily life, and has recently been widely used.
이러한 통상의 의료용 실 즉, 봉합사는 나일론 또는 합성수지 등과 같이 장력 강도가 좋은 외줄 실로서, 해당 실의 표면에는 갈고리 모양의 가시돌기(이하, '코그'라 함)들이 일정한 방향으로 형성(가시 돌기가 마주보는 방향이거나 지그재그인 방향으로 기울어지게 돌출시킨 형태)되어 절개된 피부 봉합시 또는 피부 견인시 지지력이 향상되도록 형성된다.Such a normal medical thread, that is, a suture, is a single-line thread with good tensile strength, such as nylon or synthetic resin, and hook-shaped spinous projections (hereinafter referred to as 'cogs') are formed in a certain direction on the surface of the thread (the spinous projections are facing each other or protruding obliquely in a zigzag direction) to improve the supporting force when suturing the incised skin or pulling the skin.
한편, 종래의 봉합사 원사는 주로 일본으로부터 수입되고 있는데, 이렇게 수입된 봉합사는 구입 원가가 높아서 경제성이 떨어지는 단점이 있으며, 실질적인 의료 및 성형 시술시에도 기능성이나 제품성(낮은 연신율과 가공 물성이 좋지 않아 제품의 품질이 좋지 못함) 자체가 나빠 의료 후 시술 만족도가 높지 못하다는 평가가 일반적이다.On the other hand, conventional suture yarns are mainly imported from Japan, and the imported sutures have a disadvantage in that their economic feasibility is low due to the high purchase cost. It is common to evaluate that the quality of the product itself is bad and the satisfaction with the post-medical procedure is not high.
참고로, 현재 봉합사 제품 중에는 국산품이 있기는 하나 제조된 원료의 성능이 좋지 못하여 제품 수요가 매우 낮아 수입품에 대체되지 못하고 있는 실정이다. For reference, although there are currently domestic products among suture products, the performance of manufactured raw materials is not good, so the demand for the products is very low, so they cannot be replaced by imported products.
따라서, 최근 당 업계에서는 원가절감과 함께 성능이 향상된 봉합사의 국산화를 추진하고 있으며, 이러한 관심과 수요에 따라 봉합사의 국내 제작 연구(조성물 원료 연구)가 활발하게 진행되고 있는 실정이다. Therefore, in recent years, the industry has promoted the localization of a suture with improved performance along with cost reduction, and in accordance with such interest and demand, research on domestic manufacturing of a suture (research on raw materials for a composition) is being actively conducted.
본 발명의 목적은 인체에 무해하고 안전하며 사용 후 생분해되어 친환경적이고, 사출성형시 가공물성이 우수하며, 연신율이 높아 사출 후 봉합사로의 연성(늘림성과 늘림 안정성)이 크게 향상되는 것을 특징으로 하는 고기능 봉합사 제조용 생분해성 고분자 수지 조성물 및 이로부터 제조된 고기능 봉합사를 제공하는 것이다.The object of the present invention is harmless to the human body, safe, biodegradable after use, eco-friendly, excellent processing properties during injection molding, and high elongation, so that the ductility (stretchability and stability of stretching) of the suture after injection is greatly improved. It is to provide a biodegradable polymer resin composition for manufacturing a high-function suture and a high-function suture prepared therefrom.
상기 과제를 해결하기 위해 본 발명의 발명자들은 봉합사 원자재인 고분자 수지(원료)를 국산화하고 고기능화 함으로서, 우수한 제작성 또는 가공성(사출성과 연성)이 확보되도록 하되, 생분해성에 의한 안정성과 친환경성이 보장되며, 조직 내 고정과 견인 강도가 향상되어 의료 또는 시술 대상 조직이 원활하게 복원되도록 하는 혼합된 고분자를 이용한 고기능의 봉합사를 제조하고자 하였다.In order to solve the above problems, the inventors of the present invention localize and highly functionalize the polymer resin (raw material), which is a raw material for sutures, to ensure excellent manufacturability or processability (ejectability and ductility), but to ensure stability and eco-friendliness by biodegradability, In this study, we tried to manufacture a high-performance suture using a mixed polymer that improves tissue fixation and traction strength so that the tissue to be medically or surgically treated can be smoothly restored.
따라서, 본 발명은 락타이드 중합체(PLA) 및 카프로락톤 중합체(PCL)를 제습, 건조, 혼합 및 압축하여 시표를 제조하는 단계;를 통하여 고기능 봉합사의 기본 시표 조성물이 제조된다.Therefore, in the present invention, a basic sample composition of a high-function suture is prepared through the steps of preparing a sample by dehumidifying, drying, mixing, and compressing the lactide polymer (PLA) and the caprolactone polymer (PCL).
이에 상기 카프로락톤 중합체(PCL) : 락타이드 중합체(PLA)의 질량비는 10 내지 30% : 70 내지 90% 인 것이 바람직하다.Accordingly, the mass ratio of the caprolactone polymer (PCL):lactide polymer (PLA) is preferably 10 to 30%:70 to 90%.
본 발명에 있어서, 본 발명의 제조방법에 따라 혼합된 락타이드 중합체(PLA) 및 카프로락톤 중합체(PCL)는 PLA/PCL 혹은 PLCL혹은 PLACL로 혼용되어 사용될 수 있다.In the present invention, the lactide polymer (PLA) and the caprolactone polymer (PCL) mixed according to the manufacturing method of the present invention may be used in combination as PLA/PCL, PLCL, or PLACL.
일 일시예에 있어서, 본 발명에 따른 봉합사는 PLA/PCL 원료 제조사에 따른 비교 분석, 배합비율 및 압출 공정에 따른 PLA/PCL 블렌드 칩(Chip)의 화학적 특성평가 및 생산 공정에 따른 초기 PLA/PCL 블렌드 봉합사 물리적 특성평가를 실시하였다. In one embodiment, the suture according to the present invention is the initial PLA / PCL according to the comparative analysis according to the PLA / PCL raw material manufacturer, the chemical characterization of the PLA / PCL blend chip according to the blending ratio and the extrusion process, and the production process Blend suture physical properties were evaluated.
그 결과 본 발명에 따른 봉합사는 사출물 성형 및 연신율, 연성 등이 개선됨을 확인하였다.As a result, it was confirmed that injection molding, elongation, and ductility of the suture according to the present invention were improved.
본 발명의 제조방법에 있어서, PLA 및 PCL 혼합물 제조를 위해 온도조절과 자동투입이 가능한 이축 압축기를 사용하였다. In the production method of the present invention, a twin-screw compressor capable of temperature control and automatic input was used for the production of PLA and PCL mixtures.
즉, 본 발명에서 압축하는 단계는 이축 압축기를 이용하여 피딩 온도 95 내지 105℃, 믹싱 온도 130 내지 170℃, 다이 온도 165 내지 175℃ 조건 하에서 진행되는 것일 수 있다.That is, the compressing step in the present invention may be performed using a twin-screw compressor under conditions of a feeding temperature of 95 to 105 °C, a mixing temperature of 130 to 170 °C, and a die temperature of 165 to 175 °C.
본 발명에 있어서, 시표를 제조하는 단계는 상기 압축 후 스크류 속도 250 내지 270 rpm 및 피딩 속도 15 내지 18 rpm 조건 하에서 진행되는 것일 수 있다.In the present invention, the step of preparing the sample may be performed under conditions of a screw speed of 250 to 270 rpm and a feeding speed of 15 to 18 rpm after the compression.
본 발명의 다른 측면에서, 본 발명은 고기능 봉합사 제조용 생분해성 고분자 수지 조성물로부터 고기능 봉합사를 제조할 수 있는데, 이는 시표를 용융하여 펠릿을 제조하는 단계; 상기 펠릿을 금형 사출기에 투입하여 봉합사 사출물을 제조하는 단계; 그리고 봉합사 사출물을 대기 중 또는 수중에서 인장하여 길게 연신하는 단계로 제조된다. In another aspect of the present invention, a high-function suture can be prepared from a biodegradable polymer resin composition for preparing a high-function suture, which includes preparing a pellet by melting a sample; preparing an injection-molded suture thread by injecting the pellet into an extruding mold; And it is prepared by a step of stretching the injection-molded suture in the air or in water to lengthen it.
이때, 본 발명의 봉합사는 외주면에 돌기를 형성시킨 코그(Cog)형인 봉합사이다.At this time, the suture of the present invention is a cog-type suture having protrusions formed on the outer circumferential surface.
본 발명에서, "포함한다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성 요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.In the present invention, the term "comprises" or "has" is intended to designate that there is a feature, number, step, operation, component, part, or combination thereof described in the specification, but one or more other features It should be understood that the presence or addition of numbers, steps, operations, components, parts, or combinations thereof is not precluded.
본 출원에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다.Terms used in this application are only used to describe specific embodiments, and are not intended to limit the present invention. Singular expressions include plural expressions unless the context clearly dictates otherwise.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.The advantages and features of the present invention, and how to achieve them, will become clear with reference to the detailed description of the following embodiments. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various different forms, and only the present embodiments will complete the disclosure of the present invention and allow common knowledge in the art to which the present invention belongs. It is provided to fully inform the holder of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명에 따른 봉합사는 인체에 무해하고 안전하며 사용 후 생분해되어 친환경적이고, 사출성형시 가공물성이 우수하며, 연신율이 높아 사출 후 봉합사로의 연성(늘림성과 늘림 안정성)이 크게 향상되는 효과가 있다.The suture according to the present invention is harmless and safe to the human body, is biodegradable after use, is environmentally friendly, has excellent processing properties during injection molding, and has a high elongation rate, so the ductility (stretchability and stability of stretching) of the suture after injection is greatly improved. .
도 1은 본 발명에 따른 펠릿 제조 공정의 일환으로서, 본 발명에 따라 제조된 PLACL 압출 과정을 보여준다.
도 2는 본 발명에 따른 펠릿 제조 공정의 일환으로서, 본 발명에 따라 제조된 PLACL 압출 결과를 보여준다.
도 3은 본 발명에 따른 펠릿 제조 공정의 일환으로서, 본 발명에 따른 PLACL 시작품(펠릿) 제조공정을 보여준다.
도 4는 본 발명에 따라 코그가 일체화된 구조의 단선형 봉합사 설계도를 보여준다. (사출물의 기본 형상 설계)
도 5는 본 발명에 따라 코그가 일체화된 구조의 단선형 봉합사 설계도를 보여준다. (시사출 금형 설계)
도 6은 본 발명에 따라 코그가 일체화된 구조의 단선형 봉합사 설계도를 보여준다. (구간치수)
도 7은 본 발명의 임시 사출 조건에 따라 제조된 결과를 보여준다.
도 8은 본 발명에 따른 사출 조건 확립을 위한 임시 사출물 분석 결과를 보여준다.
도 9는 본 발명에 따라 제조된 PLACL 10% 칩 및 PLACL 15% 칩의 열 가공성 테스트 결과를 보여준다.
도 10은 본 발명에 따른 일체화된 코그 봉합사 설계 (2D 및 3D)를 보여준다.
도 11은 본 발명에 따른 PLA 원소재 GPC 분석 결과를 보여준다.
도 12는 본 발명에 따른 두 가지 다른 가열/냉각 속도에서 PLACL 15%의 시차 주사 열량계(DSC) 분석 결과를 보여준다.
도 13은 본 발명에 따른 PLA/PCL5, 10, 15% 칩에 대한 2차 히팅 사이클의 DSC 온도 기록도를 보여준다.
도 14는 본 발명에 따른 PLA/PCL 블렌드 칩의 화학적 구조 분석을 위한 ATR-FTIR (IR Spectral Interpretation)을 측정한 결과를 보여준다.
도 15는 본 발명에 따라 PCL 함량이 다른 PLA/PCL 혼합물의 ATR-FTIR 스펙트럼 결과를 보여준다.
도 16은 본 발명에 따른 PLA/PCL 블렌드 시료의 회절 피크의 상대적 위치를 보여주는 선택된 재료의 XRD 패턴을 보여준다. (a) PCL (b) PLA (c) PLACL 5 (d) PLACL 10 (e) PLACL 151 shows a PLACL extrusion process prepared according to the present invention as part of the pellet manufacturing process according to the present invention.
Figure 2 shows the result of extrusion of PLACL prepared according to the present invention as part of the pellet manufacturing process according to the present invention.
Figure 3 shows a PLACL prototype (pellet) manufacturing process according to the present invention as part of the pellet manufacturing process according to the present invention.
4 shows a design diagram of a single-line suture having a structure in which a cog is integrated according to the present invention. (Basic shape design of injection molding)
5 shows a design diagram of a single-line suture structure in which a cog is integrated according to the present invention. (trial injection mold design)
6 shows a design diagram of a single-line suture having a structure in which a cog is integrated according to the present invention. (Section size)
7 shows the results produced according to the temporary injection conditions of the present invention.
8 shows the result of analyzing the temporary injection molding material for establishing injection conditions according to the present invention.
9 shows the thermal processability test results of the PLACL 10% chip and the PLACL 15% chip manufactured according to the present invention.
10 shows integrated cog suture designs (2D and 3D) according to the present invention.
11 shows the results of GPC analysis of the PLA raw material according to the present invention.
Figure 12 shows the results of differential scanning calorimetry (DSC) analysis of
13 shows DSC thermograms of the second heating cycle for PLA/PCL5, 10, and 15% chips according to the present invention.
14 shows the results of ATR-FTIR (IR Spectral Interpretation) measurement for chemical structure analysis of the PLA/PCL blend chip according to the present invention.
15 shows the ATR-FTIR spectrum results of PLA/PCL mixtures with different PCL contents according to the present invention.
16 shows XRD patterns of selected materials showing the relative positions of diffraction peaks of PLA/PCL blend samples according to the present invention. (a) PCL (b) PLA (c) PLACL 5 (d) PLACL 10 (e)
이하 하나 이상의 구체예를 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 하나 이상의 구체예를 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are intended to illustrate one or more specific examples, and the scope of the present invention is not limited to these examples.
[실시예][Example]
제조예 1: PLA/PCL의 원료 배합 및 PLA/PCL 블렌딩 칩 제조Preparation Example 1: PLA/PCL raw material mixing and PLA/PCL blending chip manufacturing
1) 원재료1) Raw materials
2) PLACL 블렌드의 제조2) Preparation of PLACL blends
- 수분 제거 전처리 : 제습 건조기(ASF-50) 80℃, 10시간 - Water removal pretreatment: dehumidifying dryer (ASF-50) 80℃, 10 hours
- 고분자 칩 제조 장비 : 이축 압축기(Twin screw extruder), ((주)진산PRM, 주문제작)- Polymer chip manufacturing equipment: twin screw extruder, (Jinsan PRM Co., Ltd., custom-made)
[표 1] PLA/PCL 블렌딩 조건[Table 1] PLA/PCL blending conditions
PLA와 PCL의 블렌드 제조를 위하여 온도저절과 자동투입이 가능한 이축 압축기를 사용하였음. PLACL 블렌드 제조의 각각의 수지 질량비를 95:5, 90:10, 85:15로 혼합하였다.A twin-screw compressor capable of temperature control and automatic injection was used to manufacture the blend of PLA and PCL. Each resin mass ratio of the PLACL blend preparation was mixed at 95:5, 90:10, and 85:15.
블렌드의 제조는 혼합한 후 이축 압출기를 사용하여 피딩온도 100℃, 믹싱 온도 130 내지 170℃, 다이 온도 170℃로 각각 고정한 다음 스크류(screw) 속도 250 내지 270 rpm 및 피딩(feeding) 속도 15 내지 18 rpm으로 제조하였다. After mixing, the blend was prepared using a twin-screw extruder to set a feeding temperature of 100 ° C, a mixing temperature of 130 to 170 ° C, and a die temperature of 170 ° C, respectively, at a screw speed of 250 to 270 rpm and a feeding speed of 15 to 18 made at rpm.
이때 다이에서 제조된 시표는 상분리 현상을 억제하기 위하여 물에 냉각시키고, 건조 후 펠렛으로 제조하였다.At this time, the sample prepared in the die was cooled in water to suppress the phase separation phenomenon, and after drying, it was made into a pellet.
압출 결과, PLACL 5% 배합비율에서는 팰릿 생산이 불가하였으며, PLACL 10 및 PLACL 15에서는 균질성이 확인되어 압출물을 절단기에 공급하여 제작함으로써 PLACL 시작품인 펠릿을 제조하였다.As a result of the extrusion, it was impossible to produce pellets at the 5% blending ratio of PLACL, and homogeneity was confirmed in
제조예 2: PLACL 봉합사 개발을 위한 초기 금형 설계 제작 및 임시 사출Preparation Example 2: Initial mold design fabrication and temporary injection for developing a PLACL suture
1) 코그가 일체화된 구조의 단선형 봉합사 제조를 위한 사출물1) Injection product for manufacturing a single-line suture with an integrated cog structure
코그가 일체화된 구조의 단선형 봉합사 개발을 위한 초기 금형 설계의 구간치수 조건은 다음과 같다(도 6).The section size conditions of the initial mold design for the development of a single-line suture with a cog-integrated structure are as follows (FIG. 6).
[표 2][Table 2]
1) 사출 조건 확립을 위한 임시 사출1) Temporary injection to establish injection conditions
[표 3] 임시 사출 조건[Table 3] Temporary Injection Conditions
사출 분석 시, 흐름성은 소재의 특성도 영향이 있으나 사출기의 온도, 압력, 시간 등의 영향으로 미성형, Burr 발생, 밀도 등에 영향을 줄 수 있다.In the case of injection analysis, flowability is also influenced by the material properties, but it can affect short shots, burr generation, and density due to the influence of temperature, pressure, and time of the injection machine.
사출 조건 확립을 위한 임시 사출물 분석 결과, 1:1 조건을 설정 진행함에 따른 애로점을 확인하였다 (도 7).As a result of the analysis of the temporary injection molding material for establishing the injection conditions, difficulties were confirmed as the 1:1 condition was set (FIG. 7).
실시예 1: 열 가공성 테스트를 통한 가 연신 공정 연구Example 1: Study of temporary stretching process through thermal processability test
앞서 제조된 PLACL 10 칩 및 PLACL 15의 열 가공성 테스트를 진행하였다.The heat processability test of the previously manufactured
그 결과, 도 9와 같이 PLACL10% 칩은 흐름성 차이로 인한 미성형이 다수 발생하고, 연신율의 차이가 발생하였으며, 뻣뻣하였다. 이와 달리 PLACL 15% 칩은 PLACL10% 칩 대비 사출물 형성 및 연신율, 연성 등이 개선됨을 확인하여 최종 시제품을 제작하였다.As a result, as shown in FIG. 9, the PLACL 10% chip had a lot of short molding due to the difference in flowability, a difference in elongation, and was stiff. In contrast, the final prototype was fabricated after confirming that the PLACL 15% chip improved injection molding, elongation, and ductility compared to the PLACL10% chip.
실시예 2: PLA/PCL 원료 비교 분석Example 2: Comparative analysis of PLA/PCL raw materials
1) PLA 원소재 GPC (gel permeation chromatography) 분석 결과1) Results of PLA raw material GPC (gel permeation chromatography) analysis
[표 4][Table 4]
표 4 및 도 11과 같이, 네이쳐웍스의 경우 중량평균분자량(Mw)이 252,239이고 토탈코비온는 216,203임을 확인하였다.As shown in Table 4 and FIG. 11, in the case of Nature Works, it was confirmed that the weight average molecular weight (Mw) was 252,239 and the total cobion was 216,203.
2) PLA/PCL 원소재 용융흐름지수 측정2) PLA/PCL raw material melt flow index measurement
- Melt Flow Indexer (WL-1400 ㈜위드랩) : 190℃, 2.16kg- Melt Flow Indexer (WL-1400 With Lab Co., Ltd.) : 190℃, 2.16kg
[표 5] PLA/PCL 배합비율에 따른 블렌딩의 용융흐름지수[Table 5] Melt flow index of blending according to PLA/PCL mixing ratio
[표 6] PLA의 원소재에 따른 PLACL 15%의 용융흐름지수[Table 6] Melt flow index of PLACL 15% according to the raw material of PLA
실시예 3: 배합비율 및 압출 공정에 따른 PLA/PCL 블렌드 칩의 화학적 특성평가Example 3: Evaluation of Chemical Characteristics of PLA/PCL Blend Chips According to Mixing Ratio and Extrusion Process
1) 열적특성 평가1) Evaluation of thermal characteristics
시차열량분석기(DSC: DSC-60A, Shimadzu)를 이용하여 측정하였다.It was measured using a differential calorimetry (DSC: DSC-60A, Shimadzu).
열이력을 같게 하기 위하여 시료를 우선 승온속도 10 ℃/min로 200 ℃까지 가열하한 후 -100 ℃까지 - 10 ℃/min으로 냉각시켰다.In order to equalize the thermal histories, the sample was first heated to 200 °C at a heating rate of 10 °C/min, and then cooled to -100 °C at -10 °C/min.
이후 다시 10 ℃/min로 200 ℃까지 승온시키며 열적특성을 조사하였다.Thereafter, the temperature was raised to 200 °C at 10 °C/min and the thermal properties were investigated.
PLA은 약 174℃ 사이에 용융 거동이 나타냈고 PCL은 56.3℃에서 용융 거동을 나타낸다. PCL 함량이 5% 증가할수록 PLA에서 보여지는 Tm 온도는 약 -1 ℃씩 감소하였고 PCL 함량 15% 감소로 인해 PCL에서 보여지는 Tm 온도는 약 -4 ℃가 감소함을 확인할 수 있었다. 또한 PLACL은 도 12와 같이 동일한 온도에서 각각 독립적으로 나타났으며, 이를 통해 상용성이 없음을 확인하였다.PLA exhibited melting behavior between about 174°C and PCL exhibited melting behavior at 56.3°C. As the PCL content increased by 5%, the Tm temperature shown in PLA decreased by about -1 ℃, and it was confirmed that the Tm temperature shown in PCL decreased by about -4 ℃ due to the decrease in PCL content by 15%. In addition, PLACL appeared independently at the same temperature as shown in FIG. 12, and through this, it was confirmed that there was no compatibility.
[표 7] PLA/PCL 블렌딩 칩 2차 히팅 사이클의 열분석 데이터[Table 7] Thermal analysis data of PLA/PCL blending chip 2nd heating cycle
2) 구조분석을 위한 ATR-FTIR 측정2) ATR-FTIR measurement for structural analysis
PLA/PCL 블렌드 칩의 화학적 구조를 조사하기 위해 적외선분광 흡수기(Fourier Transform Infrared Specroscopy, ThermoFisher Scientific, USA)를 이용하여 4000~400 cm-1 파장범위의 ATR-FTIR을 분석하였다. 선택된 스펙트럼의 시료에 대하여 주파수의 위치들과 픽의 크기를 분석하여 chemical functional group을 확인하였다.In order to investigate the chemical structure of the PLA/PCL blend chip, ATR-FTIR was analyzed in the wavelength range of 4000 to 400 cm-1 using an infrared spectroscopic absorber (Fourier Transform Infrared Specroscopy, ThermoFisher Scientific, USA). The chemical functional group was confirmed by analyzing the positions of the frequencies and the size of the pick for the sample of the selected spectrum.
그 결과, 도 14와 같이 PCL 칩은 알코올(alcohol), 올레핀(olefin), ㅈ지집지방족 알데하이드(aliphatic aldehydes), 지방족 작용기(aliphatic functional group)를 나타내었고, PLA 칩은 지방족 에스테르 작용기(aliphatic ester functional group)를 나타내었으며, PLACL 블렌드 시료의 경우 지방족 아세테이트 에스테르(aliphatic acetate esters)로 나타내었다.As a result, as shown in FIG. 14, the PCL chip showed alcohol, olefin, aliphatic aldehydes, and aliphatic functional groups, and the PLA chip showed aliphatic ester functional groups. group), and in the case of the PLACL blend sample, it was expressed as aliphatic acetate esters.
또한, PLA와 PCL은 모두 유사한 구조를 가진 지방족 폴리에스터로 알려져 있다. 도 15와 같이, ATR-FTIR 스펙트럼에서 각각 2943 cm-1, 1723 cm-1 또는 1750 및 1171 cm-1에서 C-H, C=O 및 C-O 피크가 명확하게 확인할 수 있었다. 블렌드된 PLACL 칩의 C=O stretching 피크는 PCL의 함량이 증가된 PLA 칩(1723 cm-1)에서 PCL 칩(1750 cm-1)으로 이동됨을 확인할 수 있었다. 원소재에 따른 블렌드된 PLACL의 경우 혼합된 결과로 새로운 피크는 없으며, PLA와 PCL의 두 성분을 모두 보여주는 FT-IR 스펙트럼을 확인할 수 있었다.Also, both PLA and PCL are known aliphatic polyesters with similar structures. As shown in FIG. 15, C-H, C=O, and C-O peaks were clearly identified at 2943 cm-1, 1723 cm-1, or 1750 and 1171 cm-1, respectively, in the ATR-FTIR spectrum. It was confirmed that the C=O stretching peak of the blended PLACL chips moved from the PLA chip (1723 cm-1) with increased PCL content to the PCL chip (1750 cm-1). In the case of blended PLACL according to the raw material, there is no new peak as a mixed result, and the FT-IR spectrum showing both components of PLA and PCL was confirmed.
3) XRD(X-ray diffractogram) 결정 구조 변화 확인3) XRD (X-ray diffractogram) Confirm crystal structure change
결정화 특성은 EMpyrean 회절기 (독일)를 사용하여 XRD 데이터를 얻었다. 제조된 PLACL 샘플의 XRD 측정은 60 kV 및 55mA에서 이루어졌다. Cu-Kα 방사선원을 사용하여 0°에서 60°까지의 2θ 범위에서 0.06°/s의 스캔 속도로 시료를 스캔하였다. d-spacing은 브래그의 법칙 (nλ = 2 d sin θ)으로부터 얻었고, 여기서 θ는 회절 각이고, λ는 파장 ( λ = 1.54056 A(옹스트롬), Cu target) 결정화도는 0°부터 60°까지의 범위에서 XRD 세기 데이터로부터 면적 적분법을 실시하여 결정화도를 결정하였다.Crystallization characteristics were obtained from XRD data using an EMpyrean diffractometer (Germany). XRD measurements of the prepared PLACL samples were made at 60 kV and 55 mA. The sample was scanned at a scan rate of 0.06°/s in the 2θ range from 0° to 60° using a Cu-Kα radiation source. d-spacing was obtained from Bragg's law (nλ = 2 d sin θ), where θ is the diffraction angle and λ is the wavelength (λ = 1.54056 A (Angstrom), Cu target). Crystallinity ranges from 0° to 60°. The crystallinity was determined by performing the area integration method from the XRD intensity data.
도 16과 같이, PCL 시료에서는 2θ = 21.3, 22.0, 23.6, 26.2, 28.9, 35.5, 39.0, 47.1, 48.1, 57.0°에서 서로 다른 회절 피크값이 나타나며, PLA는 2θ = 16.5, 18.9, 29.4°에서 주요 회절 피크값이 나타나며, 이를 하기 표 8에 그 결과 값을 나타내었다.As shown in FIG. 16, the PCL sample shows different diffraction peak values at 2θ = 21.3, 22.0, 23.6, 26.2, 28.9, 35.5, 39.0, 47.1, 48.1, and 57.0 °, and the PLA at 2θ = 16.5, 18.9, 29.4 ° The main diffraction peak values are shown, and the resulting values are shown in Table 8 below.
[표 8][Table 8]
PLACL 시료는 PLACL 5의 시료의 경우 2θ = 16.4, 18.7에서 2개의 회절피크 있으나 PCL의 함량이 증가할수록 2θ = 16.4, 18.7, 21.2, 23.8°에서 상응하는 4개의 주요 회절 피크를 갖는다. PLACL 물질의 회절 패턴은 PLA와 PCL 모두의 특징, 즉 넓은 비정질 산란과 뚜렷한 피크를 가지고 있고, 주요 세 피크의 흡수 강도는 높은 수준의 결정성을 유도하고 있음을 알 수 있다.The PLACL sample has two diffraction peaks at 2θ = 16.4 and 18.7 in the case of the sample of
4) 압출장비의 교차오염에 따른 중금속 분석4) Heavy metal analysis according to cross-contamination of extrusion equipment
PLA, PCL 원소재 및 PLACL 블렌딩 시료의 중금속 분석은 습식 분해법을 이용하여 시료 약 0.17g을 61% HNO3 9mL와 함께 테프론 통에 넣은 후 마이크로웨이브로 190℃에서 20분간 분해한 후 100mL 부피 플라수크에 옮긴 후 3차 증류수로 눈금까지 채웠다. 2종의 표준물질을 ICP-OES(720-ES, Varian)를 사용하여 검량선을 작성하고, 각각의 시료의 함량을 분석하였다.Heavy metal analysis of PLA, PCL raw materials and PLACL blending samples was performed by using the wet digestion method. After putting about 0.17 g of the sample into a Teflon container together with 61% HNO3 9mL, it was digested in a microwave at 190℃ for 20 minutes, and then placed in a 100mL volume flask. After transfer, it was filled up to the mark with tertiary distilled water. A calibration curve was prepared using ICP-OES (720-ES, Varian) for two types of standard materials, and the content of each sample was analyzed.
[표 9] 마이크로웨이브 전처리 장버 조건[Table 9] Microwave pretreatment equipment conditions
[표 10] 중금속(카드뮴, 납) 측정결과[Table 10] Heavy metal (cadmium, lead) measurement results
그 결과, 원소재 및 제조된 PLACL 5% (PLA : PCL = 95% : 5% v/v) PLACL 10% (PLA : PCL = 90% : 10% v/v), PLACL 15% (PLA : PCL = 90% : 15% v/v) chip과 봉합사 내에 카드뮴(Cd), 납(Pb)이 검출되지 않음을 확인하였다.As a result, raw materials and manufactured
실시예 4: 생산 공정에 따른 초기 PLACL 블린드 봉합사의 물리적 특성 평가Example 4: Evaluation of physical properties of the initial PLACL blind suture according to the production process
[표 11][Table 11]
Claims (5)
상기 카프로락톤 중합체(PCL) : 락타이드 중합체(PLA)의 질량비는 10 내지 30% : 70 내지 90%이고,
상기 시표 제조를 위한 압축시에는 이축 압축기를 이용하여 피딩 온도 95 내지 105℃, 믹싱 온도 130 내지 170℃, 다이 온도 165 내지 175℃ 조건 하에서 진행되고,
상기 시표를 제조하는 단계는 압축 후 스크류 속도 250 내지 270 rpm 및 피딩 속도 15 내지 18 rpm 조건 하에서 진행되는 것인, 고기능 봉합사 제조용 생분해성 고분자 수지 조성물로 제조된 고기능 봉합사에 있어서,
상기 봉합사는 외주면에 돌기를 형성시킨 코그(Cog)형인, 고기능 봉합사.In preparing a sample by dehumidifying, drying, mixing and compressing lactide polymer (PLA) and caprolactone polymer (PCL),
The mass ratio of the caprolactone polymer (PCL):lactide polymer (PLA) is 10 to 30%: 70 to 90%,
Compression for preparing the sample is performed using a twin-screw compressor under the conditions of a feeding temperature of 95 to 105 ° C, a mixing temperature of 130 to 170 ° C, and a die temperature of 165 to 175 ° C,
In the high-function suture made of the biodegradable polymer resin composition for preparing a high-function suture, wherein the step of preparing the sample is performed under conditions of a screw speed of 250 to 270 rpm and a feeding speed of 15 to 18 rpm after compression,
The suture is a high-function suture of a cog type in which protrusions are formed on the outer circumferential surface.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220122046A KR102506968B1 (en) | 2022-09-27 | 2022-09-27 | A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220122046A KR102506968B1 (en) | 2022-09-27 | 2022-09-27 | A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102506968B1 true KR102506968B1 (en) | 2023-03-07 |
Family
ID=85513638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220122046A KR102506968B1 (en) | 2022-09-27 | 2022-09-27 | A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102506968B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102640305B1 (en) * | 2023-05-24 | 2024-02-26 | (주)동원메디칼 | Mold for forming sutures that can minimize burrs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010049377A (en) * | 1999-05-21 | 2001-06-15 | 니시오카 요시아키 | Monofilament and process for producing the same |
KR101057376B1 (en) | 2010-10-20 | 2011-08-17 | 한스바이오메드 주식회사 | Bioabsorbable suture having barbed structures on the surface and the method of its manufacture |
-
2022
- 2022-09-27 KR KR1020220122046A patent/KR102506968B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010049377A (en) * | 1999-05-21 | 2001-06-15 | 니시오카 요시아키 | Monofilament and process for producing the same |
KR101057376B1 (en) | 2010-10-20 | 2011-08-17 | 한스바이오메드 주식회사 | Bioabsorbable suture having barbed structures on the surface and the method of its manufacture |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102640305B1 (en) * | 2023-05-24 | 2024-02-26 | (주)동원메디칼 | Mold for forming sutures that can minimize burrs |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105038165B (en) | Biological base thermoplastic elastomer with shape memory function and preparation method thereof | |
Matzinos et al. | Processing and characterization of starch/polycaprolactone products | |
Tesfaye et al. | Nanosilk-grafted poly (lactic acid) films: Influence of cross-linking on rheology and thermal stability | |
DE69919450T2 (en) | Aromatic liquid crystalline polyesters and resin composition made therefrom | |
CN101805937B (en) | Filament bundle for degrading cigarette, preparation method thereof, and preparation method of filter stick | |
KR102506968B1 (en) | A biodegradable polymer resin composition for manufacturing high-performance sutures and high functional suture prepared thereof | |
KR101464496B1 (en) | Process for manufacturing bio-degradable fibers and fibers produced thereby | |
DE2827289A1 (en) | MIXED POLYMERIZES OF LACTIDES AND GLYCOLIDES AND PROCESS FOR THEIR PRODUCTION | |
CN101878330B (en) | Methods for making polylactic acid stereocomplex fibers | |
CN113278268A (en) | High-toughness polyester composite material and preparation method thereof | |
EP0835894B1 (en) | Triblock terpolymer, its use for medical products and process for its preparation | |
CN107011647A (en) | It is a kind of can body temperature response shape memory high molecule material and preparation method thereof | |
El-Hadi | Influence of microcrystalline cellulose fiber (MCCF) on the morphology of poly (3-hydroxybutyrate)(PHB) | |
Zheng et al. | Preparation, characterization, and reaction kinetics of poly (lactic acid)/amidated graphene oxide nanocomposites based on reactive extrusion process | |
CN1869290A (en) | Sea-island composite superfine staple and its preparation method | |
CN102584567B (en) | Efficient polylactic acid nucleating agent, and preparation method and application thereof | |
JP5139841B2 (en) | Polylactic acid primary fiber, method for producing the same, and chip used in the method | |
KR20240037995A (en) | Biocomposites based on biodegradable polymers | |
CA3204737A1 (en) | Biodegradable non-woven fabric and method for producing molded body | |
CN114106534A (en) | PLA/PHA heat-resistant straw and preparation method thereof | |
Senna et al. | Compatibilization of low‐density polyethylene/plasticized starch blends by reactive compounds and electron beam irradiation | |
Gao et al. | An investigation of the crystallinity in vibration assisted injection molded poly-lactic ACID | |
CN114149668A (en) | Preparation method of PBAT (poly (butylene adipate-co-terephthalate)) based material with enhanced rigidity and toughness of mesomorphic phase | |
JP2020518691A (en) | Method for manufacturing composite material | |
PL241655B1 (en) | Method of producing a biodegradable highly filled composite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |